

This article was downloaded by:

On: 22 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713454007>

Constituents from the testas of *Castanea mollissima* Blume with α -glucosidase inhibitory activity

Hui-Yuan Gao^a; Di Wu^b; Chuan Lu^a; Xiao-Min Xu^a; Jian Huang^a; Bo-Hang Sun^a; Li-Jun Wu^a

^a School of Traditional Chinese Medicines, Shenyang Pharmaceutical University, Shenyang, China ^b The Liaoning Provincial Public Security Office, Shenyang, China

Online publication date: 04 February 2010

To cite this Article Gao, Hui-Yuan , Wu, Di , Lu, Chuan , Xu, Xiao-Min , Huang, Jian , Sun, Bo-Hang and Wu, Li-Jun(2010) 'Constituents from the testas of *Castanea mollissima* Blume with α -glucosidase inhibitory activity', *Journal of Asian Natural Products Research*, 12: 2, 144 – 149

To link to this Article: DOI: 10.1080/10286020903451757

URL: <http://dx.doi.org/10.1080/10286020903451757>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

NOTE

Constituents from the testas of *Castanea mollissima* Blume with α -glucosidase inhibitory activity

Hui-Yuan Gao^a, Di Wu^b, Chuan Lu^a, Xiao-Min Xu^a, Jian Huang^a,
Bo-Hang Sun^a and Li-Jun Wu^{a*}

^aSchool of Traditional Chinese Medicines, Shenyang Pharmaceutical University, Shenyang 110016, China; ^bThe Liaoning Provincial Public Security Office, Shenyang 110032, China

(Received 27 October 2009; final version received 29 October 2009)

In the screening of biologically active constituents from medicinal plants, the 75% EtOH extract of the testas of *Castanea mollissima* Blume showed potent α -glucosidase inhibitory activity. By means of various chromatographic methods, the extract gave a new dammarane-type triterpene **1** along with 17 known compounds. The structure of **1** was determined to be 3 β -acetoxy-20-oxo-21-nordammaran-23-oic acid by HRMS and NMR studies including 2D NMR experiments. The new compound and some known compounds showed potent α -glucosidase inhibitory activity with acarbose as a positive control.

Keywords: *Castanea mollissima* Blume; 3 β -acetoxy-20-oxo-21-nordammaran-23-oic acid; α -glucosidase inhibitory activity

1. Introduction

Type 2 diabetes is a multi-factorial disease characterized by high level of blood glucose, insulin, and impaired insulin action. The number of diabetic complaints is continuously growing with a currently estimated worldwide incidence of about 194 million people and is expected to increase to 330 million by 2025 [1]. Inhibitors of glycosidase have the potential for the treatment of various disorders and diseases such as diabetes, cancers, and AIDS [2]. Recently, intestinal α -glucosidase inhibitors were thought to be powerful therapeutic agents in carbohydrate metabolic disorders, especially diabetes mellitus.

Castanea mollissima Blume is a perennial woody plant and widely cultivated in Europe, North America, and Asia (especially in China) as the economic crop

for its sweet edible kernels, which has also been used to treat gastroenteritis, bronchitis, and regurgitation in traditional Chinese medicines for centuries [3]. In the screening of biologically active constituents from medicinal plants, the 75% EtOH extract of the testa of *C. mollissima* Blume showed much stronger α -glucosidase inhibitory activity than other plants. By means of various chromatographic methods, the extract gave a new dammarane-type triterpene along with 17 known compounds. This report describes the isolation and the structural elucidation of the constituents from the testas of *C. mollissima*, together with their α -glucosidase inhibitory activity.

2. Results and discussion

The 75% EtOH extract of the testas of *C. mollissima* was portioned between

*Corresponding author. Email: wulijun111@hotmail.com

petroleum ether (PE), CH₂Cl₂, EtOAc, *n*-BuOH, and H₂O. The PE- and CH₂Cl₂-soluble fractions showed potent α -glucosidase inhibitory activity. These fractions were successively separated by several methods to give a new compound **1** along with 17 known compounds **2–18**.

Compound **1** was obtained as colorless needles, with $[\alpha]_D^{20} + 45.3$ ($c = 0.75$, CHCl₃). Its molecular formula was established as C₂₈H₄₄O₅ by a pseudo-molecular ion peak in HR-FAB-MS at m/z 461.3267 [M+H]⁺. The absorption bands at 3361, 2918, 2850, 1710, 1463, 1216, 1087, 1048, 759 cm⁻¹ in the IR spectrum suggested the presence of hydroxyl, alkyl, carboxyl, ester functions, and so on. The ¹H NMR spectrum (600 MHz, CDCl₃) showed the presence of six methyl groups at δ_H 0.99,

0.88, 0.86, 0.85, 0.87, 2.06 (each 3H, s), one oxygen-substituted methine group at δ_H 4.46 (1H, dd, $J = 5.7, 11.1$ Hz), and other alkyl proton signals (Table 1). The ¹³C NMR and DEPT spectra of **1** showed the presence of an acetoxy group (δ_C 21.3, 171.1), five methyl carbons (δ_C 15.5, 16.3, 28.0, 16.5, 15.8), one carbon with oxygenated function (δ_C 80.9), two carbonyl groups (δ_C 176.5, 212.3), along with other alkyl groups including five methine, 10 methylene, and four quaternary carbons. The spectral character and signal patterns of compound **1** (Table 1) indicated that it was a 3 β -OH dammarane-type triterpene derivative [4]. The side chain linked with C-17 could be determined by the HMBC experiment completely. In the HMBC spectrum, H_{a,b}-22 [δ_H 2.79

Table 1. The ¹H NMR (600 and 150 MHz, CDCl₃), ¹³C NMR, and HMBC spectral data of compound **1**.

No.	δ_H (J , Hz)	DEPT	δ_C	HMBC (H \rightarrow C)
1	1.05 td (5.4, 10.8), 1.67 m	CH ₂	38.8	C-19, 2, 10, 9
2	1.62 overlap, 1.63 overlap	CH ₂	23.7	C-3, 10, 1
3	4.46 dd (5.7, 11.1)	CH	80.9	CH ₃ CO, C-26, 4, 25
4		C	37.9	
5	0.83 d (1.8)	CH	55.9	C-4
6	1.46 td (2.4, 6.6), 1.52 m	CH ₂	18.1	C-7, 8, 10
7	1.28 m, 1.57 dd (3.6, 7.8)	CH ₂	35.5	C-8, 18, 6
8		C	40.5	
9	1.30 m	CH	50.6	C-11, 18, 10, 8
10		C	37.1	
11	1.51 m, 1.26 m	CH ₂	21.2	C-12, 10, 8
12	1.61 m, 1.22 m	CH ₂	25.5	C-11, 9
13	1.96 m	CH	45.3	C-20, 14, 27
14		C	50.1	
15	1.65 m, 1.15 td (1.6, 9.6)	CH ₂	31.6	C-16, 17, 13, 14
16	1.71 m, 1.94 m	CH ₂	26.2	C-20, 17, 14, 15
17	2.64 m	CH	53.3	C-13, 12, 22
18	0.99 s 3H	CH ₃	15.5	C-14, 8, 9, 7
19	0.88 s 3H	CH ₃	16.3	C-1, 10, 9
20		C	212.3	
22	2.79 overlap, 2.80 overlap	CH ₂	37.4	C-20, 24
23	2.66 overlap, 2.67 overlap	CH ₂	27.5	C-22, 24
24		C	176.5	
25	0.86 s 3H	CH ₃	28.0	C-3, 5, 4, 26
26	0.85 s 3H	CH ₃	16.5	C-3, 5, 4, 25
27	0.87 s 3H	CH ₃	15.8	C-15, 14, 8, 13
CH ₃ C=O	2.06 s 3H	CH ₃	21.3	CH ₃ C=O
CH ₃ C=O		C	171.1	

(overlap, 1H), 2.80 (overlap, 1H)] showed correlations with C-20, 24 (δ_C 212.3, 176.5), meanwhile $H_{a,b}$ -23 [δ_H 2.66 (overlap, 1H), 2.67 (overlap, 1H)] showed correlations with C-22 (δ_C 37.4) and C-24. In addition, the corresponding cross-peak between H-3 at δ_H 4.46 (1H, dd, $J = 5.7, 11.1$ Hz) and the carbonyl carbon (δ_C 171.1) of the acetoxy group was also found, which suggested that C₃-OH was acylated. The relative configuration of compound **1** was confirmed by its NOESY spectrum (Figure 1). The correlations between H-3/CH₃-25, CH₃-26/CH₃-19/CH₃-18/H-13, and H-17/CH₃-27 indicated the fused form of A–D rings of **1** having the same stereochemistry as that of dammarane-type triterpene derivatives. Based on the above analysis, compound **1** was determined as 3 β -acetoxy-20-oxo-21-nordammaran-23-oic acid (Figure 1).

Structures of the known compounds were identified by means of ¹H NMR, ¹³C NMR, and [α]_D data as scoparone (**2**) [5], scopoletin (**3**) [6], *p*-hydroxybenzoic acid (**4**), protocatechuic acid (**5**), gallic acid (**6**), vanillic acid (**7**) [7], eupatilin (**8**) [8], jaceosidin (**9**) [9], 6-methoxytricin (**10**) [10], stigmast-4-en-6 β -ol-3-one (**11**) [11], pulvinatadione (**12**) [12], stigmastane-3 β , 6 α -diol (**13**) [13], 7-oxo- β -sitosterol (**14**) [14], cycloart-25-ene-3 β ,24*R*-diol (**15**) [15], 3 β -hydroxy-9,19-cycloart-24-oic acid (**16**), clovane-2,9-diol (**17**) [16], and palmitoylglycerol (**18**) [17] (Figure 2).

Table 2 indicated that the plant extract tested by screening showed significant

inhibitory activity, and it was found that the activity occurred in all fractions. Each fraction caused a 50% inhibition concentration (IC₅₀) value in a potent effect.

Sixteen compounds **1–14**, **17**, and **18** were tested for their α -glucosidase inhibitory activity. The results are shown in Table 3. Compounds **2** and **3** were coumarins and showed potent activity, while compounds **4–7** showed no inhibition according to their IC₅₀ values. Flavonoid derivatives **8** and **9** exhibited different results, although they have the same skeleton. In addition, the inhibitory activities of compounds **15** and **16** could not be tested for their low yields. Compounds **11–14**, with a steroid-type skeleton, showed the most potent inhibitory activity against α -glucosidase. Compound **1**, a nordammarane derivative, showed similar significant activity to that of compounds **11–14**, which indicated that the presence of the multiple rings in the structures might be the important factor for their activities.

This result may be helpful to clarify the importance of exploiting its useful resource for this plant.

3. Experimental

3.1 General experimental procedures

Optical rotations were recorded on a Perkin-Elmer 341 polarimeter at room temperature. IR spectra were recorded on KBr disks with a Bruker IFS-55 spectrometer (Fallanden, Switzerland). NMR spectra (¹H, ¹³C, and 2D NMR) were




Figure 1. The structure and key HMBC and NOESY correlations of compound **1**.




Figure 2. Structures of compounds 8–17.

obtained on a Bruker Avance 600 instrument (Bruker, Rheinstetten, Germany) at 600 MHz for 1H NMR and 150 MHz for ^{13}C NMR. The high-resolution electrospray ionization mass spectra (HR-ESI-MS) were recorded on a Bruker micro-TOF-Q mass spectrometer. Silica gel for column chromatography (200–300 mesh) and for TLC plates (GF₂₅₄) was purchased from Qingdao Marine Chemical Ltd (Qingdao, China). The plates were checked under UV light (254 and 365 nm) and detected with 5% vanillin and 10% H₂SO₄ in EtOH. A molecular device spectrophotometer was used for the measurement of enzyme inhibition.

Table 2. α -Glucosidase inhibitory activities of extracts from the testas of *C. mollissima*.

Extracts	Concentration (mg/ml)	Inhibitory rate (%)	IC ₅₀ (mg/ml)
75% EtOH	0.9	49.4	0.952
PE	1.5	95.6	0.368
CH ₂ Cl ₂	0.9	87.8	0.346
EtOAc	1.5	78.4	0.963
<i>n</i> -BuOH	0.9	58.1	0.591

3.2 Plant material

Testas of *C. mollissima* Blume were collected in September 2005 at Qianxi County in Hebei Province of China and identified by Prof. Qi Shi Sun (Shen Yang Pharmaceutical University), and the voucher specimen is deposited at the same department (No. ZB2005-027).

3.3 Extraction and isolation

Dried powder of the testas of *C. mollissima* Blume (10 kg) was extracted

Table 3. α -Glucosidase inhibitory activities of some compounds from the testas of *C. mollissima*.

Compounds	IC ₅₀ (μ M)
1	0.01
2	0.45
3	0.91
8	0.49
11	0.13
12	0.19
13	1.05
14	0.12
17	0.74
18	0.46
Acarbose	5.83

with 75% EtOH under reflux successively for three times. The crude extract (800 g) obtained by vacuum concentration was suspended in water (1000 ml) and successively extracted with PE, CH₂Cl₂, EtOAc, and *n*-BuOH. The PE fraction (40 g) was subjected to silica gel column chromatography with a gradient of PE–acetone (100:1–1:1) to afford four fractions. Fraction 1 (1.2 g) was further performed by Sephadex LH-20 (CHCl₃–MeOH, 1:1) to provide compound **11** (49 mg). Fraction 2 (45 mg) was further performed by Sephadex LH-20 (CHCl₃–MeOH, 1:1) to provide compound **15** (5 mg). Fraction 3 (2.1 g) was further performed by Sephadex LH-20 (CHCl₃–MeOH, 1:1) and recrystallized to provide compounds **10** (52 mg), **12** (35 mg), and **16** (4 mg). Fraction 4 (0.7 g) was further subjected to silica gel column chromatography (PE–CH₃COCH₃, 10:1) and Sephadex LH-20 (CHCl₃–MeOH, 1:1) to provide compounds **1** (8 mg), **14** (8 mg), and **18** (6 mg).

The CH₂Cl₂ fraction (27 g) was subjected to silica gel column chromatography with a gradient of CH₂Cl₂–MeOH (100:1–1:1) to afford three fractions. Fraction 1 (1.3 g) was further subjected to silica gel column chromatography (PE–CH₃COCH₃, 10:1) and Sephadex LH-20 (CHCl₃–MeOH, 1:1) to provide compounds **2** (10 mg) and **3** (8 mg). Fraction 2 (2.2 g) was further performed by Sephadex LH-20 (CHCl₃–MeOH, 1:1) and recrystallized to provide compounds **8** (28 mg) and **9** (35 mg). Fraction 3 (4.1 g) was further subjected to silica gel column chromatography (CH₂Cl₂–MeOH, 12:1) and Sephadex LH-20 (CHCl₃–MeOH, 1:1) to provide compounds **7** (12 mg), **13** (15 mg), and **17** (6 mg).

The EtOAc fraction (20 g) was subjected to silica gel column chromatography with a gradient of CH₂Cl₂–MeOH (100:1–1:1) to afford two fractions. Fraction 1 (3.6 g) was further performed by Sephadex LH-20 (CHCl₃–MeOH, 1:1)

to provide compound **4** (14 mg). Fraction 2 (12.9 g) was further performed by Sephadex LH-20 (CHCl₃–MeOH, 1:1) and recrystallized to provide compounds **5** (20 mg) and **6** (20 mg).

3.3.1 3β-Acetoxy-20-oxo-21-nordammaran-23-oic acid (**1**)

Colorless needles (CDCl₃), mp 65–67°C; $[\alpha]_D^{20} + 45.3$ ($c = 0.75$, CHCl₃); IR (KBr, cm⁻¹): 3361, 2918, 2850, 1710, 1463, 1382, 1216, 1087, 1048, 879, 759, 667; ¹H and ¹³C NMR spectral data, see Table 1; HR-FAB-MS: m/z 461.3267 [M+H]⁺ (calcd for C₂₈H₄₅O₅, 461.3267).

3.4 Glycosidase inhibition assay

Enzymes of α-glucosidase and *p*-nitrophenylglucopyranoside (PNPG) were purchased from Sigma Chemical Company (Shanghai, China). Acarbose was purchased from Germany Bayer Chemical Ltd (Shanghai, China). The glycosidase inhibition assay was performed according to the reported methods [18] with slight modification. Thirty microliters of 0.02 U/μl α-glucosidase enzyme in 0.2 M phosphate buffer (pH 6.8) and in the presence or absence of various concentrations of test compounds in 0.2 M phosphate buffer (pH 6.8) were incubated in 96-well plates at 37°C for 10 min, and then 140 μl of 0.02 M PNPG in 0.2 M phosphate buffer (pH 6.8) was added, and the plate was incubated at 37°C for another 30 min. The reaction was quenched by the addition of 0.2 M Na₂CO₃ solution (2 ml). Acarbose was tested as a positive control. The increment in absorption at 450 nm due to the hydrolysis of PNPG by glycosidase was monitored on a microplate spectrophotometer (Bio-Rad, Philadelphia, PA, USA). The concentration of samples required to inhibit 50% of their activity under the assay conditions was defined as the IC₅₀ value.

Acknowledgements

We thank Mrs Wen Li, Ms Yi Sha, and Ms Weiming Cheng of the Analytical Centers of the Shenyang Pharmaceutical University for recording NMR spectra and HR-ESI-MS. This work was supported by the Scientific Project Research of Hebei Province in China.

References

- [1] W. Dong, T. Jespersen, M. Bols, T. Skrydstrup, and M.R. Sierks, *Biochemistry* **35**, 2788 (1996).
- [2] S.A. Ross, E.A. Gulve, and M. Wang, *Chem. Rev.* **104**, 1255 (2004).
- [3] J.W. Jiang, *Yao Yong Zhi Wu Ci Dian* (Tianjin Scientific Publishing House, Tianjin, 2005), p. 153.
- [4] T.J. Sch, M.R. Hil, and G. Wil, *Planta Med.* **69**, 258 (2003).
- [5] X.D. Xu and J.S. Yang, *China J. Chin. Mat. Med.* **30**, 398 (2005).
- [6] J.F. Xu and L.Y. Kong, *China J. Chin. Mat. Med.* **26**, 178 (2001).
- [7] Q. Chen, L.J. Wu, and L.J. Ruan, *J. Shenyang Pharm. Univ.* **19**, 257 (2002).
- [8] J. Zhang, D.W. Qian, Y.B. Li, and Z.Q. Yin, *Nat. Prod. Res. Dev.* **18**, 71 (2006).
- [9] T. Xie, J. Liu, J.Y. Liang, Z.M. Zhang, and X.L. Wei, *China J. Nat. Med.* **3**, 86 (2005).
- [10] Y.R. Deng, L. He, W.Q. Li, and H.Q. Wang, *Chin. Tradit. Herb Drugs* **35**, 622 (2004).
- [11] Z. He, Y.G. Luo, H.J. Li, and G.L. Zhang, *Nat. Prod. Res. Dev.* **18**, 238 (2006).
- [12] A.Q. Khan and A. Malik, *Phytochemistry* **28**, 2859 (1989).
- [13] S.L. Mao, S.M. Sang, A.N. Li, and Z.L. Chen, *Nat. Prod. Res. Dev.* **12**, 14 (2000).
- [14] R.Y. Yan and S.Y. Chen, *China J. Chin. Mat. Med.* **32**, 1653 (2007).
- [15] C.H. Ma, T.F. Huang, H.Y. Qi, B.G. Li, and G.L. Zhang, *China J. Appl. Environ. Biol.* **11**, 265 (2005).
- [16] J.G. Shi, Y.P. Shi, and Z.J. Jia, *Phytochemistry* **45**, 343 (1997).
- [17] J.J. Zhu, C.F. Zhang, M. Zhang, and Z.T. Wang, *China J. Chin. Mat. Med.* **31**, 1691 (2006).
- [18] T. Matsui, T. Ueda, T. Oki, K. Sugita, N. Terahara, and K. Matsumoto, *J. Agric. Food Chem.* **49**, 1948 (2001).